Alzheimer’s Biomarkers Consortium – Down Syndrome: ABC-DS (Christian & Hartley)

The National Institutes of Health-funded Alzheimer’s Biomarkers Consortium – Down Syndrome (ABC-DS), a large multi-center research initiative to find biomarkers to track Alzheimer’s disease in Down syndrome. The Waisman Center is part of this multi-site …

Thoughts of gratitude: The Dewey family is a catalyst of support for the Waisman Center

Individuals with Down syndrome are at higher risk of developing Alzheimer’s disease, and it typically presents it at an earlier age than the general population. It is estimated that 90% of people with Down syndrome will have developed Alzheimer’s by age 65.

Studying the connection between Alzheimer’s and Down syndrome for Down syndrome awareness month

By Emily Leclerc, Waisman Science Writer The month of October is Down Syndrome Awareness Month and is dedicated to not only raising awareness about Down syndrome but also to celebrating the abilities and accomplishments of …

New NIH-funded initiative will examine Alzheimer’s disease in people with Down syndrome

A team of researchers at the University of Wisconsin–Madison is part of a new multi-institution effort to better understand Alzheimer’s disease in adults with Down syndrome. Adults with Down syndrome are at high risk for …

Mancheski Foundation funds next-gen research on Down syndrome and Alzheimer’s

A gift from the Mancheski Foundation continues to provide integral support to doctoral student Matthew Zammit as he furthers his research on the progression of Alzheimer’s disease in individuals with Down syndrome. Zammit is beginning …

Bradley T Christian, PhD – Slide of the Week

 Individuals with Down syndrome (DS) are at increased risk of developing Alzheimer’s disease (AD) and show the earliest signs of amyloid-β (Aβ) deposition in the striatum. The metric for tracking Aβ burden using PET radiotracers frequently uses average standard uptake value ratios (SUVr) in signature regions of the brain specific to Aβ deposition.